← Back to all trials
Not Yet Recruiting
NCT05618119
[18F]MC225 PET to Evaluate Gender Differences in BBB P-gp Function
Conditions: Gender
Sex: All
Ages: 50 Years – 80 Years
Healthy volunteers: 1
Phase: NA
Enrollment: 10
Sponsor: University Medical Center Groningen
Summary
P-gp is one of the main efflux transporters at the blood-brain barrier and is responsible for the transport of a variety of neurotoxic substances, including pharmaceuticals.
Multiple studies report gender differences in therapeutic outcomes, toxicity and side effects for many drug agents.
P-gp plays an important role in the bio-availability, drug distribution, metabolism and elimination of pharmaceuticals labelled as P-gp substrates (e.g. the majority of antidepressants and antipsychotics).
A difference in P-gp function was already reported in hepatic P-gp expression.
The aim of the current study is to evaluate the influence of gender on cerebral P-gp function.
Outcomes of this study can be of great importance in gender-based prescription of P-gp substrate pharmaceuticals.
Eligibility Criteria
Inclusion Criteria:Healthy volunteersExclusion Criteria:Use of medication with a known effect on the BBB P-glycoprotein transporterAny history of neurological or psychiatric conditions affecting the BBB P-glycoprotein function
Source: ClinicalTrials.gov (NCT05618119). StuddyBuddy aggregates publicly available trial information.